Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia ; volume:18 ; number:1 ; day:15 ; month:11 ; year:2018 ; pages:1-5 ; date:12.2018
BMC cancer ; 18, Heft 1 (15.11.2018), 1-5, 12.2018
- Urheber
-
Bertamini, Luca
Nanni, Jacopo
Marconi, Giovanni
Abbenante, Mariachiara
Robustelli, Valentina
Bacci, Francesco
Matti, Antonella
Paolini, Stefania
Sartor, Chiara
Monaco, Silvia Lo
Fontana, Maria Chiara
De Polo, Stefano
Cavo, Michele
Curti, Antonio
Martinelli, Giovanni
Papayannidis, Cristina
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-5026-x
- URN
-
urn:nbn:de:101:1-2018121519404329719011
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bertamini, Luca
- Nanni, Jacopo
- Marconi, Giovanni
- Abbenante, Mariachiara
- Robustelli, Valentina
- Bacci, Francesco
- Matti, Antonella
- Paolini, Stefania
- Sartor, Chiara
- Monaco, Silvia Lo
- Fontana, Maria Chiara
- De Polo, Stefano
- Cavo, Michele
- Curti, Antonio
- Martinelli, Giovanni
- Papayannidis, Cristina
- SpringerLink (Online service)
Ähnliche Objekte (12)
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Management of relapsed-refractory diffuse large B cell lymphoma
Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Management of relapsed-refractory diffuse large B cell lymphoma
Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Management of relapsed-refractory diffuse large B cell lymphoma
Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia